Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) FCF Margin (2024 - 2025)

Historic FCF Margin for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to 294.08%.

  • Prelude Therapeutics' FCF Margin rose 6178900.0% to 294.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 955.1%, marking a year-over-year change of. This contributed to the annual value of 1480.74% for FY2024, which is N/A changed from last year.
  • Latest data reveals that Prelude Therapeutics reported FCF Margin of 294.08% as of Q3 2025, which was up 6178900.0% from 519.92% recorded in Q4 2024.
  • In the past 5 years, Prelude Therapeutics' FCF Margin ranged from a high of 294.08% in Q3 2025 and a low of 911.97% during Q3 2024